The European Unified Patent Court Clears Curio Seeker With Respect To Claim 1 Of EP 2697391 Asserted By 10x Genomics
Portfolio Pulse from Benzinga Newsdesk
The European Unified Patent Court ruled that Curio Seeker does not infringe on 10x Genomics' patent claim, with no expected impact on Curio's business. The decision is appealable, and the main action is still pending.
May 01, 2024 | 7:27 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics' patent claim against Curio Seeker was not upheld by the European Unified Patent Court, but the decision is open to appeal.
The court's decision directly involves 10x Genomics, but since the decision is open to appeal and the main action remains pending, the immediate financial impact on TXG is uncertain. The ruling may not significantly affect investor sentiment in the short term, given the ongoing nature of the legal process and the specific focus on patent claims.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80